MetVital Key Personnel

Alan Cash is the founder and Chief Executive Officer of MetVital, Inc., where he directs scientific research, technology development, and collaborations with academic and research institutions.

A serial entrepreneur and innovator, Mr. Cash has received recognition associated with the White House, Inc. 500, Ernst & Young Entrepreneur of the Year, Deloitte & Touche Technology Fast 50, and Top 100 Hot Firms.

Throughout his career, he has developed and licensed technologies to major international companies, including Mitsubishi Heavy Industries and Vivendi. He also has extensive experience working with U.S. federal agencies, including the US FDA, Department of Energy, Department of Defense and Environmental Protection Agency.

Mr. Cash conducted pioneering research into the stabilization of oxaloacetate and its potential role as a caloric restriction mimetic. His work has contributed to research collaborations involving the University of California San Diego, UCLA, the University of Kansas, Pennington Biomedical Research Center, and the National Institute on Aging, part of the National Institutes of Health.

His early investigations into oxaloacetate helped establish the scientific foundation for continued research into its potential applications across a range of human health conditions.

Mr. Cash holds a Master of Science in Physics from the University of Oklahoma.

David Conway oversees clinical trials at MetVital, bringing more than 25 years of experience in the pharmaceutical, biopharmaceutical, and medical diagnostics industries.

His expertise encompasses clinical research and development, clinical operations, regulatory submissions, and the management of complex clinical programs in the United States and Europe.

Throughout his career, Mr. Conway has held leadership responsibilities for clinical and medical operations, including the oversight of multinational clinical studies, clinical research teams, and regulatory development programs. His experience includes preparing clinical protocols, investigator brochures, statistical analysis plans, clinical study reports, and regulatory submissions to U.S. and European authorities.

Mr. Conway has directed and coordinated large, multinational pivotal clinical studies contributing to the regulatory approval of innovative pharmaceuticals, biologics, and diagnostic products. These include HYQVIA, MabThera SC, Herceptin SC, Anzemet®, Infergen®, Nutre-Store L-Glutamine®, and the NGAL diagnostic CE Mark.

His extensive experience in clinical development and regulatory strategy supports MetVital's commitment to conducting rigorous clinical research and advancing promising scientific discoveries.

Mr. Conway holds a Bachelor of Science in Microbiology from Colorado State University, a Master of Science in Pharmaceutical Sciences from the University of Missouri–Kansas City, and Medical Technologist certification, MT(ASCP), from Trinity Lutheran Hospital in Kansas City, Missouri.